Social Behavior
Leqembi’s Expansion and Blood Test Impact: Analyst Sees Gradual Uptake Boost
Leqembi; Eisai; Biogen; Alzheimer’s disease; FDA approval; blood test; launch; maintenance dosing; autoinjector; subcutaneous; market adoption
Novo Nordisk and Septerna Forge $2.2B+ Collaboration on Oral Obesity and Diabetes Drugs
Novo Nordisk; Septerna; GPCR; oral drugs; obesity; type 2 diabetes; cardiometabolic diseases; GLP-1; GIP; glucagon receptors; small molecule therapies; collaboration; pharmaceuticals
Accelerating Clinical Trial Excellence: A Seamless IRB & IBC Collaboration
Clinical trials, IRB, IBC, collaboration, streamlined review, multi-institutional research, regulatory efficiency, research acceleration, biosafety, human subject protection
Trump signs sweeping executive order to cut US drug prices by ‘up to 90%’
Prices, HHS, United States, Transplant Registry Unified Management Program, Policy
Argenx brews up DTC push for Vyvgart Hytrulo prefilled syringe in generalized myasthenia gravis
Vyvgart Hytrulo, prefilled syringe, FDA approval, self-administration, generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), DTC campaign, patient empowerment
ElevAAte and the push for East Asian American leaders in biopharma
ElevAAte, biopharma, East Asian American, Leadership, leaders, Asian Americans, Mentorships, East Asian Americans, Ken Song
Cigna’s Evernorth unveils 2 new programs aimed at GLP-1s
Programs – Publication Format, Glucagon-Like Peptide 1, Cigna ‘s, GLP-1s, Pharmacy facility, Enhance (action), Pharmaceutical Services
Regeneron crumples under the weight of missed Eylea expectations
Regeneron, United States Food and Drug Administration, earnings, Eylea, decline, Sales – occupational activity
Lilly taps Creyon’s AI-enabled oligo tech in heavily backloaded $1B deal
Creyon, Eli Lilly, Eli, Oligonucleotides
Boehringer hopes to be perfect fit for Tessellate’s lead cancer programme
Malignant Neoplasms, Boehringer, ALT-positive, Ingelheim, cellular targeting